Department of Pharmaceutical Sciences, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-Ku, Sendai 980-8574, Japan.
Faculty of Pharmaceutical Sciences, Tohoku University, 1-1 Seiryo-machi, Aoba-Ku, Sendai 980-8574, Japan.
Int J Mol Sci. 2024 Apr 7;25(7):4098. doi: 10.3390/ijms25074098.
Glycosphingolipids (GSLs), mainly located in the cell membrane, play various roles in cancer cell function. GSLs have potential as renal cell carcinoma (RCC) biomarkers; however, their analysis in body fluids is challenging because of the complexity of numerous glycans and ceramides. Therefore, we applied wide-targeted lipidomics using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with selected reaction monitoring (SRM) based on theoretical mass to perform a comprehensive measurement of GSLs and evaluate their potency as urinary biomarkers. In semi-quantitative lipidomics, 240 SRM transitions were set based on the reported/speculated structures. We verified the feasibility of measuring GSLs in cells and medium and found that disialosyl globopentaosylceramide (DSGb5 (d18:1/16:0)) increased GSL in the ACHN medium. LC-MS/MS analysis of urine samples from clear cell RCC (ccRCC) patients and healthy controls showed a significant increase in the peak intensity of urinary DSGb5 (d18:1/16:0) in the ccRCC group compared with that in the control group. Receiver operating characteristic analysis indicated that urinary DSGb5 could serve as a sensitive and specific marker for RCC screening, with an AUC of 0.89. This study demonstrated the possibility of urinary screening using DSGb5 (d18:1/16:0). In conclusion, urinary DSGb5 (d18:1/16:0) was a potential biomarker for cancer screening, which could contribute to the treatment of RCC patients.
糖脂(GSLs)主要位于细胞膜中,在癌细胞功能中发挥多种作用。GSLs 有作为肾细胞癌(RCC)生物标志物的潜力;然而,由于许多糖和神经酰胺的复杂性,它们在体液中的分析具有挑战性。因此,我们应用基于理论质量的液相色谱-串联质谱(LC-MS/MS)与选择反应监测(SRM)的广泛靶向脂质组学,对 GSL 进行全面测量,并评估它们作为尿液生物标志物的潜力。在半定量脂质组学中,根据报道/推测的结构设置了 240 个 SRM 转换。我们验证了在细胞和培养基中测量 GSL 的可行性,并发现二唾液酸神经酰胺五糖基神经酰胺(DSGb5(d18:1/16:0))增加了 ACHN 培养基中的 GSL。来自透明细胞 RCC(ccRCC)患者和健康对照者的尿液样本的 LC-MS/MS 分析显示,与对照组相比,ccRCC 组中尿 DSGb5(d18:1/16:0)的峰强度显着增加。受试者工作特征分析表明,尿 DSGb5 可作为 RCC 筛查的敏感和特异性标志物,AUC 为 0.89。这项研究表明使用 DSGb5(d18:1/16:0)进行尿液筛查的可能性。总之,尿 DSGb5(d18:1/16:0)是癌症筛查的潜在生物标志物,可有助于 RCC 患者的治疗。